TOP TEN perturbations for 38901_at (Homo sapiens)
Organism: Homo sapiens
Gene: 38901_at
Selected probe(set): 226357_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 38901_at (226357_at) across 6674 perturbations tested by GENEVESTIGATOR:
HIF-1a/HIF-2a depletion study 1 (hypoxia; HK2) / HIF-1a/HIF-2a depletion study 1 (normoxia; AB81)
Relative Expression (log2-ratio):-3.5710125Number of Samples:3 / 3
| Experimental | HIF-1a/HIF-2a depletion study 1 (hypoxia; HK2) |
| Proximal tubule epithelial cell line HK-2 with shRNA-mediated stable knock-down of HIF-1a and HIF-2a (Hypoxia-inducible factor 1-alpha and Hypoxia-inducible factor 2-alpha) 24 hours after treatment with hypoxia (20% O2). HK-2 cells were cultured in DMEM/F-12 supplemented with 10% fetal calf serum (FCS), 1% ITS, hydrocortisone, and antibiotics. The cells were incubated at 37 °C. | |
| Control | HIF-1a/HIF-2a depletion study 1 (normoxia; AB81) |
| Human podocyte cells AB81 with shRNA-mediated stable knock-down of HIF-1a and HIF-2a (Hypoxia-inducible factor 1-alpha and Hypoxia-inducible factor 2-alpha) 24 hours after treatment with normoxia (20% O2). Conditionally immortalized human podocytes AB81 were cultured under permissive conditions (33 °C) in RPMI-1640 supplemented with 10% FBS, antibiotics, and 1% ITS. Differentiation was induced by thermoshift to 37 °C in 6-well plates. |
ovarian tumor study 11 (low grade) / normal ovarian surface epithelial cell sample
Relative Expression (log2-ratio):1.5894861Number of Samples:11 / 6
| Experimental | ovarian tumor study 11 (low grade) |
| Human microdissected tumor cells from the ovary of patients with low grade serous carcinoma. | |
| Control | normal ovarian surface epithelial cell sample |
| Human microdissected ovarian surface epithelial cell sample from the ovary of healthy individuals. |
exercise study 33 (YT; fast twitch; post-exerc.) / exercise study 33 (YUT; fast twitch; post-exerc.)
Relative Expression (log2-ratio):-1.4690399Number of Samples:6 / 4
| Experimental | exercise study 33 (YT; fast twitch; post-exerc.) |
| Fast twitch myosin heavy chain muscle fibers (MHC) IIa were obtained from vastus lateralis muscle. Biopsies were taken from young trained (YT) women (23±2 years old) 4 hours after the 36th (last) exercise session. Participants underwent 12 weeks of progressive resistance training including 36 training sessions (3 days/week) with three sets of 10 bilateral knee extensions at 70–75% of their one-repetition maximum (1 RM). Fibers were separated under the light microscope and MHC isoform was determinated based on SDS-PAGE analysis. Exclusion criteria: acute/chronic illness, cardiac, pulmonary, liver, or kidney abnormalities, uncontrolled hypertension, insulin or non-insulin-dependent diabetes, abnormal blood, or urine chemistries, arthritis, a history of neuromuscular problems, tobacco smoking. Individuals, that had ever completed any formal exercise programs or physical activity outside of their activities of daily living, were excluded as well. | |
| Control | exercise study 33 (YUT; fast twitch; post-exerc.) |
| Fast twitch myosin heavy chain muscle fibers (MHC) IIa were obtained from vastus lateralis muscle. Biopsies were taken from young untrained (YUT) women (23±2 years old) 4 hours after the first resistance exercise. Fibers were separated under the light microscope and MHC isoform was determinated based on SDS-PAGE analysis. Exclusion criteria: acute/chronic illness, cardiac, pulmonary, liver, or kidney abnormalities, uncontrolled hypertension, insulin or non-insulin-dependent diabetes, abnormal blood, or urine chemistries, arthritis, a history of neuromuscular problems, tobacco smoking. Individuals, that had ever completed any formal exercise programs or physical activity outside of their activities of daily living, were excluded as well. |
connective/soft tissue cancer study 1 (PDX; connective and soft tissue, leiomyosarcoma, NOS; metastatic) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, leiomyosarcoma, NOS; primary)
Relative Expression (log2-ratio):-1.2183542Number of Samples:2 / 2
| Experimental | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, leiomyosarcoma, NOS; metastatic) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary connective and soft tissue, leiomyosarcoma, NOS of the soft tissue (subcutaneously implanted). Metastatic site of patient tumor sample is not reported. | |
| Control | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, leiomyosarcoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, leiomyosarcoma, NOS of the soft tissue (subcutaneously implanted). |
glioma study 16 (LN-18) / normal astrocyte sample
Relative Expression (log2-ratio):1.191124Number of Samples:2 / 3
| Experimental | glioma study 16 (LN-18) |
| Human glioma cell line LN018 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37C and 5% CO2. | |
| Control | normal astrocyte sample |
| Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations. |
expO breast cancer study 1 (papillary carcinoma, NOS; primary) / expO breast cancer study 1 (adenocarcinoma with squamous metaplasia; primary)
Relative Expression (log2-ratio):1.17377Number of Samples:2 / 2
| Experimental | expO breast cancer study 1 (papillary carcinoma, NOS; primary) |
| Primary tumor tissue samples obtained from the breast of patients with papillary carcinoma (NOS). | |
| Control | expO breast cancer study 1 (adenocarcinoma with squamous metaplasia; primary) |
| Primary tumor tissue samples obtained from the breast of patients with adenocarcinoma with squamous metaplasia. |
connective/soft tissue cancer study 1 (PDX; connective and soft tissue, liposarcoma, well differentiated type; primary) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, leiomyosarcoma, NOS; primary)
Relative Expression (log2-ratio):-1.1655626Number of Samples:2 / 2
| Experimental | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, liposarcoma, well differentiated type; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, liposarcoma, well differentiated type of the soft tissue (subcutaneously implanted). | |
| Control | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, leiomyosarcoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, leiomyosarcoma, NOS of the soft tissue (subcutaneously implanted). |
B-CLL study 11 (rolipram) / rolipram study 4 (normal B-cell; 20uM)
Relative Expression (log2-ratio):1.1393871Number of Samples:4 / 4
| Experimental | B-CLL study 11 (rolipram) |
| Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:--- | |
| Control | rolipram study 4 (normal B-cell; 20uM) |
| MACS purified resting B-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:--- |
peptidoglycan study 1 / mock treated neonatal neutrophils
Relative Expression (log2-ratio):-1.138773Number of Samples:3 / 3
| Experimental | peptidoglycan study 1 |
| Healthy neonatal neutrophils with ≥ 99% purity isolated from cord blood samples collected after normal, full-term, vaginal delivery treated with peptidoglycan isolated from S. aureus (10 ug/ml) for 4 hours. | |
| Control | mock treated neonatal neutrophils |
| Healthy neonatal neutrophils with ≥ 99% purity isolated from cord blood samples collected after normal, full-term, vaginal delivery mock treated for 4 hours. |
ovarian tumor study 11 (borderline) / normal ovarian surface epithelial cell sample
Relative Expression (log2-ratio):1.1175385Number of Samples:8 / 6
| Experimental | ovarian tumor study 11 (borderline) |
| Human microdissected tumor cells from the ovary of patients with low-malignant (borderline) tumors of the ovary. | |
| Control | normal ovarian surface epithelial cell sample |
| Human microdissected ovarian surface epithelial cell sample from the ovary of healthy individuals. |